Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
$123.37M
Mr. Talat Imran
114.00
San Jose, CA
Mar 22, 2018
-1.96
$-1.18
1.32
13.32
0.00%
-1.00
2.12
0.00
13.01
-61.34%
-153.07%
Similar stocks (18)
Tyra Biosciences, Inc.
TYRA
EyePoint Pharmaceuticals, Inc.
EYPT
Monte Rosa Therapeutics, Inc.
GLUE
Corvus Pharmaceuticals, Inc.
CRVS
Biomea Fusion, Inc.
BMEA
Trevi Therapeutics, Inc.
TRVI
Cabaletta Bio, Inc.
CABA
Tenaya Therapeutics, Inc.
TNYA
ALX Oncology Holdings Inc.
ALXO
PMV Pharmaceuticals, Inc.
PMVP
Protara Therapeutics, Inc.
TARA
Surrozen, Inc.
SRZN
Vincerx Pharma, Inc.
VINC
Lyra Therapeutics, Inc.
LYRA
Monopar Therapeutics Inc.
MNPR
Viracta Therapeutics, Inc.
VIRX
Vaccinex, Inc.
VCNX
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (7)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (18)
Tyra Biosciences, Inc.
TYRA
EyePoint Pharmaceuticals, Inc.
EYPT
Monte Rosa Therapeutics, Inc.
GLUE
Corvus Pharmaceuticals, Inc.
CRVS
Biomea Fusion, Inc.
BMEA
Trevi Therapeutics, Inc.
TRVI
Cabaletta Bio, Inc.
CABA
Tenaya Therapeutics, Inc.
TNYA
ALX Oncology Holdings Inc.
ALXO
PMV Pharmaceuticals, Inc.
PMVP
Protara Therapeutics, Inc.
TARA
Surrozen, Inc.
SRZN
Vincerx Pharma, Inc.
VINC
Lyra Therapeutics, Inc.
LYRA
Monopar Therapeutics Inc.
MNPR
Viracta Therapeutics, Inc.
VIRX
Vaccinex, Inc.
VCNX
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (7)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%